May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at www.sidoticonference.com/events.
Group Presentation Schedule (click on the company name to register & watch) | ||||
Wednesday, May 19th, 2021 (Day 1) | ||||
*All Times EDT | ||||
8:30-9:00 | **** | |||
9:15-9:45 | ||||
10:00-10:30 | ||||
10:45-11:15 | ||||
11:30-12:00 | **** | |||
12:15-12:45 | ||||
1:00-1:30 | ||||
1:45-2:15 | ||||
2:30-3:00 | ||||
3:15-3:45 | **** | |||
4:00-4:30 | ||||
Thursday, May 20th, 2021 (Day 2) | ||||
*All Times EDT | ||||
8:30-9:00 | **** | |||
9:15-9:45 | **** | |||
10:00-10:30 | **** | |||
10:45-11:15 | ||||
11:30-12:00 | ||||
12:15-12:45 | ||||
1x1s Only - No Presentation | Blueknight (BKEP) || LSB Industries (LXU) | |||
About Sidoti
For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $4 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a small and microcap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in North America, including many leading managers of portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the small and microcap space through our conferences (www.sidoticonference.com) and the hundreds of non-deal roadshows we host each year.
Contact
Sidoti Events Team
212-453-7031
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$2.21 |
| Daily Change: | -0.22 -9.05 |
| Daily Volume: | 28,600 |
| Market Cap: | C$54.210M |
September 16, 2024 August 07, 2024 June 25, 2024 March 26, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
